These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 28993505

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome.
    Szarvas N, Szilágyi Á, Csuka D, Takács B, Rusai K, Müller T, Arbeiter K, Réti M, Haris Á, Wagner L, Török S, Kelen K, Szabó AJ, Reusz GS, Morgan BP, Prohászka Z.
    Mol Immunol; 2016 Mar; 71():10-22. PubMed ID: 26826462
    [Abstract] [Full Text] [Related]

  • 47. Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification.
    Martín Merinero H, Zhang Y, Arjona E, Del Angel G, Goodfellow R, Gomez-Rubio E, Ji RR, Michelena M, Smith RJH, Rodríguez de Córdoba S.
    Blood; 2021 Dec 02; 138(22):2185-2201. PubMed ID: 34189567
    [Abstract] [Full Text] [Related]

  • 48. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
    Vondrák K, Seeman T.
    Transplant Proc; 2018 Apr 02; 50(3):967-970. PubMed ID: 29661469
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.
    Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M, European Working Party on Complement Genetics in Renal Diseases.
    J Am Soc Nephrol; 2013 Feb 02; 24(3):475-86. PubMed ID: 23431077
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.
    Osborne AJ, Breno M, Borsa NG, Bu F, Frémeaux-Bacchi V, Gale DP, van den Heuvel LP, Kavanagh D, Noris M, Pinto S, Rallapalli PM, Remuzzi G, Rodríguez de Cordoba S, Ruiz A, Smith RJH, Vieira-Martins P, Volokhina E, Wilson V, Goodship THJ, Perkins SJ.
    J Immunol; 2018 Apr 01; 200(7):2464-2478. PubMed ID: 29500241
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Factor H Autoantibodies and Complement-Mediated Diseases.
    Zhang Y, Ghiringhelli Borsa N, Shao D, Dopler A, Jones MB, Meyer NC, Pitcher GR, Taylor AO, Nester CM, Schmidt CQ, Smith RJH.
    Front Immunol; 2020 Apr 01; 11():607211. PubMed ID: 33384694
    [Abstract] [Full Text] [Related]

  • 56. Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome.
    Jiang H, Fan MN, Yang M, Lu C, Zhang M, Liu XH, Ma L.
    Int J Environ Res Public Health; 2016 Dec 05; 13(12):. PubMed ID: 27929404
    [Abstract] [Full Text] [Related]

  • 57. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome.
    Martínez-Barricarte R, Heurich M, López-Perrote A, Tortajada A, Pinto S, López-Trascasa M, Sánchez-Corral P, Morgan BP, Llorca O, Harris CL, Rodríguez de Córdoba S.
    Mol Immunol; 2015 Aug 05; 66(2):263-73. PubMed ID: 25879158
    [Abstract] [Full Text] [Related]

  • 58. Genetic influences on plasma CFH and CFHR1 concentrations and their role in susceptibility to age-related macular degeneration.
    Ansari M, McKeigue PM, Skerka C, Hayward C, Rudan I, Vitart V, Polasek O, Armbrecht AM, Yates JR, Vatavuk Z, Bencic G, Kolcic I, Oostra BA, Van Duijn CM, Campbell S, Stanton CM, Huffman J, Shu X, Khan JC, Shahid H, Harding SP, Bishop PN, Deary IJ, Moore AT, Dhillon B, Rudan P, Zipfel PF, Sim RB, Hastie ND, Campbell H, Wright AF.
    Hum Mol Genet; 2013 Dec 01; 22(23):4857-69. PubMed ID: 23873044
    [Abstract] [Full Text] [Related]

  • 59. Structural and functional characterization of the product of disease-related factor H gene conversion.
    Herbert AP, Kavanagh D, Johansson C, Morgan HP, Blaum BS, Hannan JP, Barlow PN, Uhrín D.
    Biochemistry; 2012 Mar 06; 51(9):1874-84. PubMed ID: 22320225
    [Abstract] [Full Text] [Related]

  • 60. Recognition of malondialdehyde-modified proteins by the C terminus of complement factor H is mediated via the polyanion binding site and impaired by mutations found in atypical hemolytic uremic syndrome.
    Hyvärinen S, Uchida K, Varjosalo M, Jokela R, Jokiranta TS.
    J Biol Chem; 2014 Feb 14; 289(7):4295-306. PubMed ID: 24344133
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.